Research

Timothy P. Cripe MD, PhD

ProfessorCollege of Medicinetimothy.cripe@nationwidechildrens.org

700 Childrens Dr Columbus OH 43205

Phone:614-722-3552Fax: 614-722-3699

Viral Oncology

General Research Interest

Oncolytic virotherapy, targeted small molecule inhibitors, non-CNS solid tumors in children

Research Description

My laboratory is interested in developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma. Our efforts are primarily focused on the development of oncolytic virotherapy as well as small molecule targeted inhibitors. Active projects include studies of the mechanism and enhancement of tumor-selective virus delivery for metastatic disease, the role and manipulation of regulatory T cells in the antiviral and antitumor immune response, the utility of incorporating therapeutic transgenes to modify the tumor microenvironment, the effect of small molecule inhibitors combined with oncolytic virus infection, and the effect of oncolytic viruses on cancer stem cells.

Transinstitutional Work

We have ongoing collaborations with Drs E.A. Chiocca and B. Kaur in the OSUCCC Department of Neurosurgery in the area of oncolytic virotherapy, with Dr. N. Ratner in the Division of Experimental Hematology & Cancer Biology at Cincinnati Children’s Research Foundation in the area of neurofibromatosis and malignant peripheral nerve sheath tumors, and with Dr. S. Wells in the Division of Hematology/Oncology at Cincinnati Children’s Research Foundation in the area of human papillomavirus-associated tumorigenesis.

Current Publications

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TPVEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.Mol Ther 21(5) 1014-23 5/1/2013
Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller JPilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.Pediatr Blood Cancer in press 4/29/2013
Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner NMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123(1) 340-7 1/2/2013
Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner NIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Cancer Res 72(20) 5317-27 10/15/2012
Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow B, Perentesis J, Serra E, Cripe T, Miller SC, Ratner NRas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18(18) 5020-30 9/15/2012
Cripe TPDiffering approaches to experimental therapeutics: are we a world apart?Mol Ther 20(9) 1649-50 9/1/2012
Kaur B, Chiocca EA, Cripe TPOncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.Curr Pharm Biotechnol 13(9) 1842-51 7/1/2012
Chernoguz A, Crawford K, Donovan E, Vandersall A, Berglund C, Cripe TP, Frischer JSEGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.J Surg Res 173(1) 1-9 3/1/2012
Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner NPreclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.Pediatr Blood Cancer 58(2) 173-80 2/1/2012
Kaimal V, Chu Z, Mahller YY, Papahadjopoulos-Sternberg B, Cripe TP, Holland SK, Qi XSaposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging.Mol Imaging Biol 13(5) 886-97 10/1/2011